(BUSINESS WIRE)–Pharming Group NV (EURONEXT: PHARM) and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the first patient was treated in their Phase 2 clinical study of Ruconest®, (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, for prophylaxis in patients with hereditary angioedema (HAE). Read more

Shares of Salix Pharmaceuticals opened today at $121 and are currently trading up at $121.12. SLXP has a 1-year high of $172.98 and a 1-year low of $86. The stock’s 50-day moving average is $109.47 and it’s 200-day moving average is $132.16.

On the ratings front, Salix Pharmaceuticals has been the subject of a number of recent research reports. In a report published on January 6, analyst Irina Rivkind from Cantor Fitzgerald reiterated a Buy rating on SLXP, with a price target of $145, which represents a potential upside of 19.8% from where the stock is currently trading. Separately, on December 18, Deutsche Bank`s Gregg Gilbert maintained a Hold rating on Salix Pharmaceuticals shares and has a price target of $107.

6 research analysts have assigned a Hold rating and 8 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is 121$ which is 0.6% above where the stock opened today.

Salix Pharmaceuticals Ltd is a specialty pharmaceutical company, which is dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases.